MedTrace Logo

Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms

NCT04368819 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-24

No results posted yet for this study

Summary

Despite numerous advances in medical treatment and revascularization procedures for the treatment of patients with stable angina, debilitating symptoms that are unresponsive to conventional therapy may occur in patients unsuitable for revascularization, a condition known as refractory angina. Allopurinol, a methylxanthine oxidase inhibitor, is widely used in the treatment of gout and asymptomatic hyperuricemia. On the other hand, the anti-ischemic effects of allopurinol have been the subject of increasing interest. Therefore, the investigators will study the safety and efficacy of allopurinol in alleviating ischemic symptoms in patients with refractory angina already on optimal medical therapy.

Conditions

  • Refractory Angina

Interventions

DRUG

Allopurinol 300 MG

Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks

DRUG

Placebo oral tablet

Placebo 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • InCor Heart Institute

    collaborator OTHER

  • Ministry of Health, Brazil

    lead OTHER_GOV

Principal Investigators

  • Luis Henrique W Gowdak, MD, PhD · Heart Institute (InCor-HCFMUSP)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2021-09-30
Completion
2021-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04368819 on ClinicalTrials.gov